OAKLAND, Calif., April 21, 2014 — Women with high levels of a common liver enzyme measured prior to pregnancy were twice as likely to subsequently develop gestational diabetes than those with the lowest levels, according to a Kaiser Permanente study published today in the journal Diabetes Care.
The liver plays an important role in regulating glucose levels in the body. The liver enzyme, called gamma-glutamyl transferase (GGT), is a common marker of liver function and has also been associated with insulin resistance, which can be a precursor to gestational diabetes and type 2 diabetes.
This study is the third in a series using the same cohort of mothers to examine the role of biomarkers prior to pregnancy in predicting the risk of gestational diabetes. The researchers ultimately hope to develop a risk model to help identify women who would benefit from interventions during the pre-conception period.
“Several biomarkers appear to be associated with the risk of gestational diabetes,” said Monique M. Hedderson, PhD, senior author of the study and research scientist with the Kaiser Permanente Division of Research in Oakland, Calif. “These studies provide evidence that women who develop gestational diabetes have metabolic abnormalities even before pregnancy. In the future, we could potentially try to prevent gestational diabetes by intervening before women get pregnant.”
Gestational diabetes, or glucose intolerance during pregnancy, has increased dramatically in recent decades and is now the most common complication of pregnancy. It can lead to adverse outcomes including larger-than-normal babies and subsequent delivery complications. Women with gestational diabetes are seven times more likely to develop type 2 diabetes later in life, and their children are at greater risk of becoming obese and developing diabetes themselves.
Using HealthConnect®, Kaiser Permanente’s electronic health records system, the researchers retrospectively identified more than 4,000 women who gave voluntary blood samples between 1985 and 1996 during routine care and subsequently delivered an infant in Kaiser Permanente’s Northern California region. Among that group, 256 women developed gestational diabetes during pregnancy and 497 did not. The blood samples were collected and frozen 7 years prior to pregnancy, on average.
After adjusting for numerous possible confounding factors, including body mass index (BMI) and alcohol use, the researchers found that women in the highest quartile of GGT had nearly twice the risk of subsequent gestational diabetes than those in the lowest quartile. No associations were found with two other commonly monitored liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
“A few studies have looked at liver enzyme levels during pregnancy and the risk of gestational diabetes, but to our knowledge this is the first to look at liver enzyme levels measured before pregnancy,” said lead author Sneha Sridhar, MPH, project coordinator with the Kaiser Permanente Division of Research.
In the previous studies, researchers reported that:
- Overweight women with low levels of the hormone adiponectin prior to pregnancy were nearly seven times more likely to develop gestational diabetes than normal weight women with high levels (August 2013).
- Women with low levels of sex hormone binding globulin were five times more likely to develop gestational diabetes than those with higher levels of the protein (February 2014).
A future study will examine the role of fat particle size in the same cohort.
In addition to Hedderson and Sridhar, co-authors of the study are: Fei Xu, MA, Jeanne Darbinian, MPH, Charles P. Quesenberry, PhD, and Assiamira Ferrara, MD, PhD, all of the Kaiser Permanente Division of Research.
The research was supported in part by the National Institute of Child Health and Human Development of the National Institutes of Health.
